While I agree with the positives of a NASDAQ listing, I would rather see management pursue a listing on the SHE (Shanghai) right now. I think there would be a lot more credibility built into the story with Chinese investors given that Shenzhen Hepalink has put over $100 million cash into the RVX program and Shenzhen Hepalink is well known and respected by Chinese investors. Hepalink trades about 6 million shares a day on the SHE and has returned over 40% this year.

The story of RVX, being basically a subsidiary of HL (as far as ownership goes), with huge potential might play very well over there. Good returns there might also amplify what could occur on Nasdaq later. Just a thought.